AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18048644 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 0
Study 18048644 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 18048644 — intervention group
Group type: COMPARATOR
Intervention: Autologous transplantation
Number of subjects: 0
Study 16548360 — intervention group
Group type: EXPERIMENTAL
Intervention: Biqi capsule (BC)
Number of subjects: 142
Study 16548360 — intervention group
Group type: COMPARATOR
Intervention: Nimesulide tablet (NT)
Number of subjects: 142
Study 12640286 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise training program (6 weeks, involving nondominant arms, isometric hand-grip contractions to 25-35% of MVC lasting 40-120 seconds, repetitive squeezing of squash and racquet balls)
Number of subjects: 5
Study 12640286 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise training program (6 weeks)
Number of subjects: 5
Study 10769442 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion endarterectomy (EEA)
Number of subjects: 600
Study 10769442 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrombendarterectomy (TEA)
Number of subjects: 600
Study 10769442 — intervention group
Group type: COMPARATOR
Intervention: Dacron patch
Number of subjects: 600
Study 10769442 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex-ultrasound
Number of subjects: 600
Study 8842602 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal GLP-I tablet (119 nmol)
Number of subjects: 8
Study 1728930 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol levels above 4.65 mmol/L (180 mg/dL)
Number of subjects: 316099
Study 1728930 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP above 110 mm Hg
Number of subjects: 316099
Study 1728930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP above 70 mm Hg
Number of subjects: 316099
Study 1728930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (high quintiles)
Number of subjects: 316099
Study 1728930 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP and diastolic BP, serum cholesterol level, and cigarettes per day
Number of subjects: 316099
Study 1728930 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP
Number of subjects: 316099
Study 6360325 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and methyl-CCNU administered in combination, given in discrete 5-day courses at 7-week intervals.
Number of subjects: 645
Study 6360325 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 645
Study 30455531 — intervention group
Group type: EXPERIMENTAL
Intervention: Results-based financing
Number of subjects: 4000000
Study 30455531 — intervention group
Group type: EXPERIMENTAL
Intervention: Input-based financing
Number of subjects: 4000000
Study 30455531 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4000000
Study 27548104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (24 mg once daily)
Number of subjects: 261
Study 27548104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 24674853 — intervention group
Group type: EXPERIMENTAL
Intervention: Park director (PD) intervention
Number of subjects: 50
Study 24674853 — intervention group
Group type: EXPERIMENTAL
Intervention: Park director and park advisory board (PD+PAB) intervention
Number of subjects: 50
Study 24674853 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 50
Study 22208555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-grain diet for 9 weeks
Number of subjects: 0
Study 22208555 — intervention group
Group type: COMPARATOR
Intervention: Regular diet for 9 weeks
Number of subjects: 0
Study 20466742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 21
Study 20466742 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 21
Study 18552625 — intervention group
Group type: EXPERIMENTAL
Intervention: BPC plus wellness training (WT)
Number of subjects: 309
Study 18552625 — intervention group
Group type: COMPARATOR
Intervention: Basic primary care (BPC)
Number of subjects: 309
Study 15791501 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 400 mg; 1200 mg/day (p.o.)
Number of subjects: 16
Study 15791501 — intervention group
Group type: COMPARATOR
Intervention: No bisphosphonates treatment
Number of subjects: 16
Study 12763321 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast visual transients appearing at various times with respect to the target change.
Number of subjects: 8
Study 10963288 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 759
Study 9421740 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal whole body hyperthermia (EWBH) at 41 degrees C
Number of subjects: 6
Study 9421740 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal whole body hyperthermia (EWBH) at 42 degrees C
Number of subjects: 6
Study 8103581 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 10
Study 8103581 — intervention group
Group type: EXPERIMENTAL
Intervention: HMPAO-SPECT
Number of subjects: 10
Study 8103581 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET and HMPAO-SPECT
Number of subjects: 10
Study 2937673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sicorten cream
Number of subjects: 247
Study 2937673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sicorten ointment
Number of subjects: 247
Study 2937673 — intervention group
Group type: COMPARATOR
Intervention: Sicorten creams and ointments
Number of subjects: 247
Study 30280658 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg IV every 2 weeks for up to 12 months)
Number of subjects: 713
Study 30280658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo every 2 weeks for up to 12 months)
Number of subjects: 713
Study 30280658 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 713
Study 30280658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study 26235391 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP of 10 cmH2 O during pre-oxygenation and induction of anaesthesia
Number of subjects: 40
Study 26235391 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 1.0 during emergence
Number of subjects: 40
Study 26235391 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 0.31 during emergence
Number of subjects: 40
Study 26235391 — intervention group
Group type: COMPARATOR
Intervention: Control group with no CPAP and FIO2 of 1.0 during emergence
Number of subjects: 40
Study 24759202 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly structured planned rest protocol with visitor and healthcare personnel restrictions
Number of subjects: 52
Study 24759202 — intervention group
Group type: COMPARATOR
Intervention: Simple planned rest period without restrictions
Number of subjects: 52
Study 22497533 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting beta-agonists (LABA)
Number of subjects: 376
Study 22497533 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 376
Study 20674826 — intervention group
Group type: EXPERIMENTAL
Intervention: pC1‐INH concentrate (Berinert) at single intravenous doses of 10 or 20 U/kg body weight
Number of subjects: 97
Study 20674826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 18715405 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg of leuprorelin acetate (3-4 weeks)
Number of subjects: 106
Study 18715405 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of cetrorelix (4-7 days)
Number of subjects: 106
Study 15916052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (78 cases)
Number of subjects: 697
Study 15916052 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (33 cases)
Number of subjects: 697
Study 12859157 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy (regimen C)
Number of subjects: 161
Study 12859157 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (regimen A and B)
Number of subjects: 161
Study 10368202 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vasoactive cream (aminophylline, isosorbide dinitrate, co-dergocrine mesylate)
Number of subjects: 14
Study 10368202 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (no pharmacologically active ingredients)
Number of subjects: 14
Study 8721690 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal hemostasis device
Number of subjects: 68
Study 1997243 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair and augmentation of the ACL with an iliotibial strip
Number of subjects: 156
Study 1997243 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair without augmentation
Number of subjects: 156
Study 1997243 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical ACL treatment
Number of subjects: 156
Study 6382700 — intervention group
Group type: EXPERIMENTAL
Intervention: Team care
Number of subjects: 130
Study 6382700 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 130
Study 31451579 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (GABAA modulator)
Number of subjects: 0
Study 31451579 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen (GABAB modulator)
Number of subjects: 0
Study 31451579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28974349 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose ICS/LABA
Number of subjects: 459
Study 28974349 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable ICS/LABA
Number of subjects: 459
Study 28974349 — intervention group
Group type: COMPARATOR
Intervention: LABA-step-off (ICS alone)
Number of subjects: 459
Study 26489028 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous cyclophosphamide (CYC)
Number of subjects: 100
Study 26489028 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mycophenolate mofetil (MMF)
Number of subjects: 100
Study 24338058 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (5 Hz, 4 pulses at 500 μs)
Number of subjects: 19
Study 24338058 — intervention group
Group type: COMPARATOR
Intervention: ACT (30% PVo2max)
Number of subjects: 19
Study 24338058 — intervention group
Group type: COMPARATOR
Intervention: PAS (resting)
Number of subjects: 19
Study 22095616 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular (RV) pacing
Number of subjects: 171
Study 22095616 — intervention group
Group type: EXPERIMENTAL
Intervention: Echo-guided cardiac resynchronisation (CRT) pacing
Number of subjects: 171
Study 22095616 — intervention group
Group type: COMPARATOR
Intervention: Non-responders group
Number of subjects: 171
Study 22095616 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT mode
Number of subjects: 171
Study 22095616 — intervention group
Group type: EXPERIMENTAL
Intervention: Echo-optimised CRT
Number of subjects: 171
Study 20584348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone-treated group
Number of subjects: 68
Study 20584348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 17115180 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.125 g kg body mass(‐1))
Number of subjects: 8
Study 17115180 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 8
Study 17115180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (HPG)
Number of subjects: 8
Study 17115180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (HYP)
Number of subjects: 8
Study 16372903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital screening invitation
Number of subjects: 1200
Study 16372903 — intervention group
Group type: COMPARATOR
Intervention: General practitioner screening invitation
Number of subjects: 1200
Study 16372903 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from test provider > 30 minutes
Number of subjects: 1200
Study 16372903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of time as a reason for non-compliance
Number of subjects: 1200
Study 16372903 — intervention group
Group type: COMPARATOR
Intervention: Accompaniment to test
Number of subjects: 1200
Study 16372903 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-receipt of screening invitation letter
Number of subjects: 1200
Study 16372903 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior screening
Number of subjects: 1200
Study 12133087 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid group (Ringer's solution infusion at 1.5 ml.kg(‐1).h(‐1) from 22:00 h until induction of anaesthesia)
Number of subjects: 48
Study 12133087 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 48
Study 12133087 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid group
Number of subjects: 48
Study 10201594 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral LASIK
Number of subjects: 357
Study 10201594 — intervention group
Group type: COMPARATOR
Intervention: Sequential bilateral LASIK
Number of subjects: 357
Study 7606406 — intervention group
Group type: EXPERIMENTAL
Intervention: Insitucat valvulotome
Number of subjects: 50
Study 7606406 — intervention group
Group type: COMPARATOR
Intervention: Hall valvulotome
Number of subjects: 50
Study 2222347 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxepa (eicosapentaenoic acid)
Number of subjects: 108
Study 2222347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 2222347 — intervention group
Group type: COMPARATOR
Intervention: Aspirin/dipyridamole
Number of subjects: 108
Study 2222347 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxepa
Number of subjects: 108
Study 658870 — intervention group
Group type: EXPERIMENTAL
Intervention: etozolin
Number of subjects: 100
Study 658870 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 31833224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 31
Study 31096728 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (Group G)
Number of subjects: 80
Study 31096728 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (Group S)
Number of subjects: 80
Study 28272120 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 47
Study 28272120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 47
Study 28272120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Imipramine + Pregabalin)
Number of subjects: 47
Study 28272120 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (monotherapy)
Number of subjects: 47
Study 28272120 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (monotherapy)
Number of subjects: 47
Study 28272120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 47
Study 25772953 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Tranexamic acid (2.5 g in 250 ml normal saline)
Number of subjects: 100
Study 25772953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study 23370316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m initially, 250 mg/m weekly thereafter) plus Bevacizumab (15 mg/kg) for six cycles combined with Paclitaxel (200 mg/m) and Carboplatin (AUC 6) for six cycles
Number of subjects: 121
Study 23370316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m initially, 250 mg/m weekly thereafter) plus Bevacizumab (15 mg/kg) for three cycles combined with Paclitaxel (200 mg/m) and Carboplatin (AUC 6) for three cycles
Number of subjects: 121
Study 21330337 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy (BFHX)
Number of subjects: 26
Study 21330337 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy (FHX)
Number of subjects: 26
Study 21330337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (both groups)
Number of subjects: 26
Study 21330337 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical salvage (both groups)
Number of subjects: 26
Study 19372349 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight (TL)
Number of subjects: 20
Study 19372349 — intervention group
Group type: COMPARATOR
Intervention: Flexible fiberoptic bronchoscope (FOB)
Number of subjects: 20
Study 17292384 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion at 90 minutes (defined as ST resolution below 50% on VCG)
Number of subjects: 400
Study 17292384 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention or coronary artery bypass grafting
Number of subjects: 400
Study 17292384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention before discharge
Number of subjects: 400
Study 17292384 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the reperfusion criteria of VCG
Number of subjects: 400
Study 15786695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline at 0.5 mg/week orally for 4 consecutive weeks
Number of subjects: 20
Study 15786695 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control group)
Number of subjects: 20
Study 17244442 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 0
Study 17244442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular injections of steroids and anti-vascular endothelial growth factor agents
Number of subjects: 0
Study 17244442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained drug release devices
Number of subjects: 0
Study 17244442 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 0
Study 17244442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheathotomy
Number of subjects: 0
Study 10371654 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg)
Number of subjects: 16
Study 10371654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8604866 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air rewarming
Number of subjects: 16
Study 8604866 — intervention group
Group type: COMPARATOR
Intervention: Cotton blankets (control group)
Number of subjects: 16
Study 1894888 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 30 en% fat, P/S = 1.0
Number of subjects: 0
Study 1894888 — intervention group
Group type: COMPARATOR
Intervention: Diet with 40 en% fat, P/S = 0.3
Number of subjects: 0
Study 1894888 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diets
Number of subjects: 0
Study 1894888 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified diet
Number of subjects: 0
Study 1894888 — intervention group
Group type: COMPARATOR
Intervention: Higher saturated fat diet
Number of subjects: 0
Study 6216427 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoid scalp lotion
Number of subjects: 30
Study 6216427 — intervention group
Group type: EXPERIMENTAL
Intervention: Betnovate scalp application
Number of subjects: 30
Study 31502856 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture (LA), administered at traditional Chinese acu-points on the affected side, once a day, 5 times a week, for 4 weeks (N=43)
Number of subjects: 84
Study 31502856 — intervention group
Group type: COMPARATOR
Intervention: Placebo Laser Acupuncture (placebo LA), administered using the same device and protocol, with the LA device switched off (N=41)
Number of subjects: 84
Study 29885054 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Training (BT)
Number of subjects: 43
Study 29885054 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctrl)
Number of subjects: 43
Study 26792354 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic thyroidectomy with central neck dissection (CND) using Da Vinci system
Number of subjects: 80
Study 26792354 — intervention group
Group type: COMPARATOR
Intervention: Open conventional approach for thyroidectomy with CND
Number of subjects: 80
Study 26792354 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic thyroidectomy with CND
Number of subjects: 80
Study 23084488 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 60
Study 23084488 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and maxillomandibular fixation
Number of subjects: 60
Study 21959345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 2128
Study 21959345 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 2128
Study 19643944 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly, supervised, outpatient‐based exercise plus unsupervised home exercise
Number of subjects: 59
Study 19643944 — intervention group
Group type: COMPARATOR
Intervention: Standard care of unsupervised home exercise
Number of subjects: 59
Study 17241480 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermic CPB (ModHT group, 28 degrees C)
Number of subjects: 20
Study 17241480 — intervention group
Group type: COMPARATOR
Intervention: Mild hypothermic CPB (MiHT group, 34 degrees C)
Number of subjects: 20
Study 16237744 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal optimization package
Number of subjects: 39
Study 16237744 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative care
Number of subjects: 39
Study 12182992 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide s.c., 100 microg three times daily (n = 33)
Number of subjects: 61
Study 12182992 — intervention group
Group type: COMPARATOR
Intervention: Diphenoxylate and atropine orally, 2.5 mg four times daily (n = 28)
Number of subjects: 61
Study 10443671 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH-(1-34)
Number of subjects: 10
Study 10443671 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH-(1-31)
Number of subjects: 10
Study 7847975 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6 doses of 2.4 g intravenously in the first 24 hours)
Number of subjects: 100
Study 7847975 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 100
Study 2382916 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carboxyhemoglobin
Number of subjects: 41
Study 2382916 — intervention group
Group type: COMPARATOR
Intervention: room air
Number of subjects: 41